Cargando…
Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer
Histone deacetylase inhibitors (HDACi) are small molecules targeting epigenetic enzymes approved for hematologic neoplasms, which have also demonstrated clinical activities in solid tumors. In our present study, we screened our internal compound library and discovered a novel HDACi, WW437, with pote...
Autores principales: | Zhang, Tao, Li, Jingjie, Ma, Xiaojun, Yang, Yang, Sun, Wei, Jin, Wangrui, Wang, Lei, He, Yuan, Yang, Feifei, Yi, Zhengfang, Hua, Yingqi, Liu, Mingyao, Chen, Yihua, Cai, Zhengdong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013969/ https://www.ncbi.nlm.nih.gov/pubmed/29759486 http://dx.doi.org/10.1016/j.ebiom.2018.05.003 |
Ejemplares similares
-
EphA5 and EphA6: regulation of neuronal and spine morphology
por: Das, Gitanjali, et al.
Publicado: (2016) -
Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma—Associations with Clinical Parameters and Patient Survival
por: Gajdzis, Malgorzata, et al.
Publicado: (2020) -
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors
por: Hatano, Manabu, et al.
Publicado: (2004) -
Targeting EphA2 in cancer
por: Xiao, Ta, et al.
Publicado: (2020) -
The efficacy of receptor tyrosine kinase EphA2 autophosphorylation increases with EphA2 oligomer size
por: Zapata-Mercado, Elmer, et al.
Publicado: (2022)